Jens Hasskarl
chief medical officer
Advesya
Basel, Switzerland
10 profile visitsSpeakerSpeakers
Board-certified hematologist team-oriented with strong leadership skills with extensive pharmaceutical experience in cell and gene therapy.
My organisation
Established by founders Christophe Ferrand and Marina Deschamps, Advesya is a spin-out from the French Blood Institute (EFS) in Besançon (France), where it is deeply integrated into the medical and research community. Fueled by experts in drug development (spanning from target validation to product launch) since it was seeded by Jeito in 2022, the company is on a mission to deliver innovative treatment options to patients with critical unmet medical needs. Advesya has quickly evolved into a clinical-stage company and is now developing novel and customized treatment modalities, including a CAR T-cell (CCTx-001) and an ADC (ADV-101) that are tailored to each disease associated with IL-1RAP dysregulation.
Speaker sessions (1)
Thursday, 10 October 2024
14:45 - 15:50
Session#2 : CAR-T cells and beyond
Format:In-person
Location:Petit Kursaal room
Track:Conference